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SUMMARY – Prostate adenocarcinoma with Paneth cell-like neuroendocrine diff erentiation is a 
rare entity. Foci of scattered cells and small clusters are found in the majority of described cases, al-
though cases with predominant Paneth cell-like features have also been recorded. Th ese cells contain 
eosinophilic cytoplasmic inclusions and lack androgen receptors, and are consequently immune to 
hormone therapy. It is, therefore, important for pathologists to recognize them. According to litera-
ture, clinical outcome depends on the standard grading of the conventional prostate cancer compo-
nent. We report a case of a 54 year-old patient with prostatic adenocarcinoma showing Paneth cell-
like neuroendocrine diff erentiation.
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Introduction
Adenocarcinoma of the prostate is the second most 
common cancer in men, with the majority of cases de-
tected after the age of 60. Th e most common adeno-
carcinoma of the prostate is acinar, but there are rare 
types of adenocarcinoma such as those with neuroen-
docrine (NE) diff erentiation. Th e signifi cance of these 
tumor subtypes lies in their potential resistance to cur-
rent therapies. Th e carcinoma with Paneth cell-like 
cells (PCLC) is one of the tumors in the group of tu-
mors with NE diff erentiation. Th ese cells are distin-
guished by prominent eosinophilic cytoplasmic. PCLC 
may be present in well-formed glands of Gleason pat-
tern 3, but can also be found in cords of cells with 
bland cytology that would typically be defi ned as 
Gleason pattern 51. It can be detected by standard mi-
croscopic analysis and immunohistochemistry staining 
with neuroendocrine markers such as synaptophysin 
and chromogranin A. Here we report a case of high 
Gleason score prostate cancer with strong Paneth cell-
like diff erentiation.
Case report
Fifty four year old man appeared to have a high 
serum prostatic-specifi c antigen (PSA) level (71.45ng/
ml) and F/T PSA ratio (13.4) in his regular physical 
examination. Fine needle core biopsy of the prostate 
was performed. Histological examination revealed ad-
enocarcinoma, Gleason score 8 (5+3), group 4, accord-
ing to WHO 2016 classifi cation. Th e patient under-
went radical prostatectomy at Sestre milosrdnice Uni-
versity Hospital Center. Th e histopathologic analysis 
of paraffi  n-embedded specimens revealed diff use 
spread of the tumor in both lobes. Tumor was com-
posed of solid, glomeruloid, cribriform and glandular 
structures aligned partly by tumor cells with promi-
nent red nucleoli and partly by round to pyramidal 
cells with markedly eosinophilic granular cytoplasm. 
Th e later component was consistent with pathological 
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features of Paneth cell-like carcinoma cells (Fig. 1A). 
Immunohistochemical analysis demonstrated positiv-
ity for chromogranin A and synaptophysin in PCLC 
(Fig. 1 B,C). Perineural and lymph capillary invasion 
was found, as well as extension through the prostatic 
capsule into periprostatic fat. Lymph nodes of para-
aortic and pelvic regions were tumor positive (Fig. 
1D). Only a few scattered Paneth cell-like cells were 
found microscopically in lymph node metastases. 
Th ree years after the initial surgery, chemotherapy, ra-
diotherapy and hormone therapy (6 cycles with 
docetaxel and prednisone), the patient was diagnosed 
with metastatic disease in Th 12 vertebra. It was poorly 
diff erentiated adenocarcinoma, without visible Paneth 
cell-like component. Th e patient underwent six more 
chemotherapy cycles with carboplatin. Th e illness was 
complicated by pneumonia and the patient was treated 
with ceftriaxone. Th e patient is currently alive and well, 
without recurrence 38 months from the diagnosis.
Discussion
NE component of normal prostate tissue consists 
of a small subset of cells, randomly scattered within 
the epithelium of the prostate gland. Th ese cells con-
tain a variety of peptide hormones, lie on the basal cell 
layer between secretory cells and are not reliably recog-
nizable by hematoxylin and eosin (HE) examination. 
Immunohistochemistry may shed light on NE diff er-
entiation, most often with synaptophysin, chromo-
granin A and CD56. Neuroendocrine cells in the pros-
tate regulate growth and diff erentiation in addition to 
the exocrine secretory process of the prostate gland.2-4
PCLC are distinct cells, easily noticeable by light 
microscopy at HE slides. Th ey contain eosinophilic cy-
toplasmic inclusions and, unlike true Paneth cells, lack 
lysozyme, but express neuroendocrine markers and 
show neurosecretory granules on electron microscopy, 
which makes them more similar to the cells of the dif-
Fig. 1. A. Microscopic appearance of prostate cancer with abundant Paneth cell-like diff erentiation (arrows), 
(HEx200); B. Cells are immunohistochemically positive for chromogranin A (100x); C. and synaptophysin 
(100x); D. Tumor metastatic to lymph node with scattered Paneth cell-like cells (arrows).
J. Šojat et al. Paneth cells in prostate
Acta Clin Croat, Vol. 57, (Suppl. 1) 2018 87
fuse neuroendocrine system.2-4 In the prostate, the 
presence of PCLC has been documented in benign 
prostatic glands, prostatic intraepithelial neoplasia, 
and prostate cancer. It was considered rare in both be-
nign and malignant prostatic diseases, but Adlakha 
and Bostwick showed in their study that PCLC is 
more common than previously thought, and although 
it represents neuroendocrine diff erentiation, it is not 
associated with tumor grade or pathologic stage5.
According to literature, focal neuroendocrine dif-
ferentiation is extensive in up to 5% of prostate can-
cers. It is considered to be associated with poor prog-
nosis, especially with high grade NE carcinoma com-
ponent (35% survival rate in 2 years in cases with neu-
roendocrine diff erentiation vs. 97% survival rate in 2 
years in cases without it)3,4. Th is may be due to high 
tumor level neuroendocrine cell products which stim-
ulate growth and lack androgen receptors in neuroen-
docrine cells, subsequently with low therapy re-
sponse3,4.
Specifi c characteristics of neuroendocrine diff eren-
tiation in prostate cancer were ignored until 2013. 
Th en a new refi ned histological classifi cation was pro-
posed by the Prostate Cancer Foundation. It imple-
mented newly acquired clinical and molecular data. 
Prostate cancer with Paneth cell-like neuroendocrine 
diff erentiation was singled out as a distinct category, 
which is generally considered to have a favorable prog-
nosis6. Th e new classifi cation was partially accepted by 
WHO in 2016. It distinguishes adenocarcinoma with 
Paneth cell-like neuroendocrine diff erentiation as a 
separate entity, along with the usual adenocarcinoma 
with neuroendocrine diff erentiation, well-diff erentiat-
ed neuroendocrine tumor, small cell neuroendocrine 
carcinoma and large cell neuroendocrine carcinoma1.
It is still important to emphasize that there are lim-
ited data on the prognostic importance of the Paneth 
cell-like diff erentiation. According to most authors, 
Paneth cell-like appearance of prostatic carcinoma 
cells should be recognized and considered as a sign of 
neuroendocrine diff erentiation due to the possible as-
sociation with resistance to hormone therapy, since 
androgen receptors are not expressed by benign or ma-
lignant prostatic neuroendocrine cells2-7.
In 2006, Tamas and Epstein demonstrated that Pa-
neth cell-like diff erentiation foci should not be as-
signed to Gleason score, since the clinical outcome 
depends on standard parameters, i.e. grading of the 
conventional prostate adenocarcinoma component7.
In a recent study of 25 prostatic adenocarcinomas 
with Paneth cell-like neuroendocrine diff erentiation, 
45% showed amplifi cation of the Aurora Kinase A 
(AURKA) gene, which was associated with a higher 
percentage of Paneth cell-like neuroendocrine diff er-
entiation throughout the tumor, ductal features and a 
higher Gleason score. AURKA has been found to be 
overexpressed in castrate-resistant prostate cancer 
with neuroendocrine diff erentiation and the hormone-
naive primary tumor. Authors suggested that AURKA 
amplifi cation may be used as a biomarker and a treat-
ment target for an aggressive form of prostate cancer 
related to androgen deprivation therapy8.
In conclusion, it is important for a pathologist to be 
aware of possible neuroendocrine diff erentiation in 
prostate cancer due to resistance to conventional hor-
monal chemotherapy, as well as possible aggressive 
forms of cancers with NE diff erentiation. Paneth cell-
like NE diff erentiation in prostate cancer is not related 
to aggressive form of cancer. AURKA gene could be a 
potential target for therapy of this tumor subtypes.
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Sažetak
KARCINOM PROSTATE S KOMPONENTOM NALIK NA PANETHOVE STANICE 
- PRIKAZ SLUČAJA
J. Šojat, B. Jurić, Š. Šoipi, M. Ulamec i B. Krušlin
Adenokarcinom prostate s neuroendokrinom diferencijacijom u obliku komponente koja nalikuje Panethovim stanicama 
je vrlo rijedak entitet. Raspršene neuroendokrine stanice nalik Panethovima mogu se naći u većini opisanih slučajeva, iako se 
nalaze i primjeri s predominantnom komponentom navedenih stanica. One sadrže eozinofi lne citoplazmatske inkluzije, a 
nedostaju im androgeni receptori te su stoga imuni na hormonsku terapiju, a što je jedan od glavnih razloga da ih patolozi 
prepoznaju. Prema dostupnoj literaturi, klinički ishod takvih tumora ovisi o standardnim parametrima, ponajprije o gradusu 
konvencionalne komponente karcinoma prostate. Ovdje opisujemo 54-godišnjeg bolesnika s adenokarcinomom prostate koji 
pokazuje neuroendokrinu diferencijaciju tipa stanica nalik Panethovim.
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